Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Citi
AstraZeneca
Harvard Business School
US Department of Justice
Farmers Insurance
Accenture

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,585,879

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,585,879 protect, and when does it expire?

Patent 7,585,879 protects YUPELRI and is included in one NDA.

This patent has thirty-six patent family members in twenty-six countries.

Summary for Patent: 7,585,879
Title:Biphenyl compounds useful as muscarinic receptor antagonists
Abstract: This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Inventor(s): Mammen; Mathai (Redwood Shores, CA), Ji; Yu-Hua (Redwood City, CA), Mu; YongQi (Los Altos, CA), Husfeld; Craig (Redwood City, CA), Li; Li (Sunnyvale, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/879,996
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 7,585,879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial Y Y FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,585,879

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048032   Try a Free Trial
Argentina 104444   Try a Free Trial
Austria 395335   Try a Free Trial
Austria 467617   Try a Free Trial
Australia 2005222411   Try a Free Trial
Brazil PI0508622   Try a Free Trial
Canada 2557479   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Merck
Colorcon
Express Scripts
US Department of Justice
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.